Dang,

I know/knew the Ampersand guys. First ran across them back in their startup days in Boston. Rick Charpie, the founder used his Dad's connections (former CEO of Cabot Corporation) and his banking training to start up the fund. Went to one of their first investor conferences. Will always remember the talk by Clayton Christiansen, who was apparently one of Rick's best friends. He's known for his economic work and being a professor at Harvard, but at the time, back in the late 80's, he was still young, smart and could deliver a tremendous talk - I was incredibly impressed. I'll always remember a guy at the event saying that when Rick and Clayton got together onstage, he thought they were going to "start levitating" because of all the positive waves. In the mid-90's, talked with them about an investment in an industrial chemicals project. But, at the time, they were transitioning towards healthcare investments more than the advanced materials/chemicals focus they'd started with.

Anyway, Stockaxe is right about finding out how the process has played out. Did they shop around, or did these guys walk in the door and negotiate an offer? What can be done to improve it? These things happen all the time. Great for management as they get to get rid of all their complaining shareholders (especially after they've screwed up or haven't performed as planned). They get to cash in their options, get a re-do with deeper pocketed, well-connected investors who have a different time-horizon than the current investors. Oh, and did I forget to mention that the new investors re-load management with new options to go along with their deep pocketed financial and contact support. Nick and team cut a fat hog. And, the new investors take away the risk of getting screwed with financing again. They bring this expertise. Take it private and then merge it or bring it out again. Wash, rinse, repeat.

Disclosure, the names and story are all from memory. So, take it with a grain of salt. Might not be accurate.

Hi North,

Just guessing, but probably not. You can bet your bottom dollar however, that they have excellent D&O coverage.

Regards.

WH

Halozyme Therapeutics announces Roche (RHHBY) receives European Commission Approval of Tecentriq SC with ENHANZE (34.43)

Unfortunately, as much as we'd like to just go out and sell our services, we need some help on timing from the approval agencies. Need more of these to roll in.

Regards,

WH

geo,

I'd like to see him post more frequently. He's currently easy to calibrate with RSI, Worden Stochastics, MA's and the Coppock Curve or whatever your flavor. So, the trading signal isn't helpful and more frequent entries won't hurt.

But, I have entered checking this board into my pre-board procedures whenever I board a United Flight. Figure if someone's posting, they can't be sitting in a pilot's seat preparing for takeoff. Cubbie as my aircraft pilot is a thought too far.

Regards,
WH

Dang, the gang's all here! Well, most anyway. Hope everyone's doing well. One thing I know. We're all a lot older.

Regards,
Wh

Geo,

Are you shorting Avid here or still just pretending?

Does it really matter? I know enough of the people on here to know that nothing this gentleman says is going to impact or change their investment decisions. On the other hand, I still fly United somewhat frequently and it does concern me when their pilots exhibit immature, childish behavior. Doesn't build confidence.

Regards,
WH

Ps. to Eb. Hope you're doing well. As an aside, is the guy on HGEN for real?

Hi Westy,

To hopefully cheer you up a bit, I'm going to repost a message from Stockaxe that was made after the last qtr. cc. I personally believe Stockaxe is one of our most sage posters when it comes to the workings of business and the markets. I've bolded the most notable piece of the post as far as I'm concerned. From 9/8, post number 344490.

Funny enough...I thought this quarter was pretty good in the context of the industry environment. They continue to grow revenue and maintain backlog despite a large portion of their bookings (early stage) basically at zero because of the environment. They are winning projects from other CDMOs that should reap major dividends in 18-24 months and could very well fill the facilities. If biotech funding were to actually come back, I think you'd see another $30-$50mm in revenue from early stage projects start to pile in. If funding is weak through the end of 2025 (which would be 4 years...kind of unprecedented), I still think Avid grows and will generate good EBITDA. What people here can't seem to understand is that incremental revenue has a 70% margin. Do that math. If they add $50mm in revenue from today's base, that's an incremental $35mm of gross profit. Gross margin and profits will very quickly rebound because of this operating leverage. The Company had decent bookings and continued on its path in a weak environment and in what is usually a slower quarter for bookings. Absent the slowdown in biotech funding, I think they would have filled facilities by the end of calendar 2024. I think that has probably been pushed by a year, but the stock will react well before they fill the facilities.

I've been involved in a few capacity expansions over the years. They usually don't ramp up as cleanly as the planners projected when they justified the project. It usually takes a bit more time. But, once they take off, the ramp goes quicker than thought. The key to it all is the part highlighted above.

Hope things improve soon. I still have some, but I'm now going to have to jump in harder once I see things turn.

Regards,

WH

Let's hope our NOL carryforwards do the same thing for Avid's market perception and stock price as Tesla's sale of emission credits did for Elon. Musk became the world's richest man by getting a few "profitable" quarters under his belt - all due to the emission credit sales, not the sale of cars.

All in the messaging. If we can somehow sell the story that toll processing drugs reduces CO2 emissions, we'd be golden!

All TIC or course. I think.

Regards,

WH

Obviously, Nick is very skilled and very good in his role. I really love how he dishes out the compliments to his team. A head coach lots of folks (superstars included) would like to play for.

Excellent cc. Hard to top that one.

Regards,

WH

Log in through the link in the email that was sent to the address you provided in your registration.

Hog,

"Notice the 11 cents a share was regarding a one-time fee of 24 million to gain 71.5 million in Revenue this year with much more expected this year and in the future as a result."

Even I'd take $71.5 million in a year for a $24 million investment. And, I'm not very bright.

Regards,
WH

Might be of interest to those invested.

https://www.zerohedge.com/energy/hydrogen-better-bridge-fuel-natural-gas

SIAP.

Regards,

WH

Just a little anecdotal note.

Doing pre-market stuff this a.m. Was listening to Maria Bartiromo on Fox Business and she interviews Joe Lonsdale who runs a large early stage investment fund, help found Palantir, etc. Impressive guy. I've seen him in interviews before.

Salient part of the interview for those involved here. Maria asked him where he was looking for the next big thing, what had his interest? Without hesitation, he said that the US's desire/need to get a handle on drug manufacturing, rip it away from China as a result of lessons learned from the Covid debacle had him looking to the contract manufacturing market. He mentioned a startup he's backing, but I missed the name.

Anyway, takeaway for me is that his is the reason institutional investors have flocked our way. These guys tend to run in packs and the idea of bringing sophisticated drug manufacturing to the US is an investment thesis most of them can understand. A second takeaway in keeping with the potential suitor theme is that while Halo, others in the manufacturing arena etc. might sound intriguing, they're not the only game in town. Don't forget about the possibility of a well funded Private Equity guy looking to roll up several pieces of the drug manufacturing pie into a really big deal. Strategic acquisitions usually pay less and keep management around. Financial guys pay more.

Just some food for thought.

WH

Protector,

Agree with your buy technique. Tends to keep you from catching that proverbial falling knife. Guess on this one, I'm buoyed by the lack of volume on the sell off - meaning the big guys aren't bailing. Just normal MM fun and games.

Don't have Bloomberg. You wouldn't happen to have numbers for cost to borrow and utilization would you?

Regards,

WH

Westy

"I don't know if we are at the bottom(although I believe we are close if not there)"

Nobody commented on my Gartley pattern comment the other day. But, since we've just about landed on the .786 Fibonacci retracement point needed to complete the C-D leg of the formation (my eyeball estimate with a little calculator help). Just fyi, my calc says that point is about 22.4.

https://www.investopedia.com/terms/g/gartley.asp For those interested. Again, this was what Protector was also talking about the other day. Don't think for a minute that market makers aren't aware of these patterns. Also, on balance volume has remained high during the sell-off. We've breached the 200 dma, etc.

Anybody else going to buy with me? Don't need more shares, but what the heck.

Regards,

WH

jbain,

By my reckoning, 23.8 or so is a beautiful bullish gartley pattern buy point. Kind of matches with Protectors "w's" sermon.

Another comment. Price means nothing without volume - both up and down. I think most people on here are amazed at the large moves down on little volume. Takes many more steps up on small volume to cover the same territory. That's the market in general - not just CDMO.

Finally, hopefully something of interest, rather than me blabbering. As of today on IBD, CDMO is rated:

Number 5 in the group of Medical-Biomed/Biotech stocks. (VRTX, AMPH, REGN, and EVO are higher)

The group unfortunately is currently ranked 123 out of 197 sectors.

Current RS (Relative Strength) rating is 96 - that's excellent.

Accumulation/Distribution Rating is B - strong.

Up/Down Volume is 1.8

% Change in Funds Owning Stock - 4%

Qtrs. of Increasing Fund Ownership - 5

Still looks awful good to me. Just saying.

Regards,

WH

Protector,

Just a little sauce for your elasticity subject. Today I sold 1000 shares 4 separate times (shares bought back in early September). All orders were thrown out as market orders just to watch the reaction. Every time, I got a price improvement over the current price. Imagine that. Nice to see the price pick up on a market sell order.

Regards,
WH

Ok, let's recap. Please feel free to add to the bullet points.

1. At 4:17 p.m. on the 25th, IBD send out a notice that CDMO will replace Cadence Bancorp (CADE) in the S&P SmallCap 600, effective prior to opening of trading on Friday, Oct. 29th. Surprise!!!

2. After hours and pre-market trading occurs which is different in nature than the small lot signaling that often happens.

3. Market opens and boom.
(a.) Huge 10%+ gap up.
(b.) Price exceeds 52 week high and all highs dating back to 2012. This is a huge deal for many traders.
(c.) Volume in 1st 10 minutes exceeds the normal average daily volume. Another big deal for many traders.

All of this is stunningly impressive to traders and should have had CDMO listed on IBD's "stocks on the move" list based on the volume and price increase. Unfortunately, even though IBD covers CDMO, they weren't listed today. Don't know why. Maybe they'll show up tomorrow.

4. Technical data from IBD.
(a.) CDMO prior to today was ranked 3rd in the Medical/Biomed/Biotech group. This group is currently ranked 81st out of the 197 groups IBD constantly ranks.
(b.) CDMO has a 97% relative strength rating, and accumulation/distribution rating of A- and an Up/Down Volume of 1.7.
(c.) Funds have increased ownership for the last 5 quarters, the sales/margin/ROE (smr) rating is A, and the 3-yr sales growth rate is 37%.

All pretty outstanding stuff.

5. From a charting perspective (for traders),
(a.) The gap over the previous 52-week high in early August is huge.
(b.) I use a MACD 24/52 vs. an EMA 18 to signal intermediate trends. The MACD crossed strongly to the upside about 2.5 weeks ago. Moving up strongly. This is good in my world.
(c.) I watch OBV (on-balance volume) closely. Since March, 2020 CDMO's been on a steady climb. Today sent it vertical.
(d.) Saw a lot of discussion about the gap and rapid rise and then the flat line. Not an expert but I have been doing this a long time and do trade a lot of "surprise factor" stocks. The rapid "first hour" rise followed by a flat line with possibly a slow bleed until the final hour is often the norm (just my observations). The pros open the market and are usually done in the first hour unless it's an unusual market day. Jr. traders take over and hold the ship steady till the pros return in the last hour. Just watching the minute chart, when the pros came back, buying picked up again.

All good stuff.

6. A few things already mentioned. Everyone knows about the institutional numbers. CDMO stock is not plentiful. Also saw mention of gaps being filled. I'm with the posters that made the observation that not all gaps get filled (may be the norm but not perfect) and the observation that the gap needing to be filled should only need to be the highs on 8/11 & 12 which is essentially where we descended to on the open today.

Anyway. Very encouraged by the day. Looking forward to the future.

Oh, oh, oh, one last point. I see a lot of folks obsessing about whether or not the company is managing the stock price properly and whether or not they're selling ATM shares to keep the price in line. Just me, and I know we're a little jaded by how past TCLN/PPHM management handled all of this, but most "good" managements don't play these game very much. They make a business growth plan and they follow it. They might be opportunistic occasionally, but usually, they keep they're nose down and take care of the things they can control. I see Nick as this kind of guy. He knows that if he keeps the team focused on adding new clients, getting production out the door and building new capacity with no hiccups on timing or costs, good things will result. The share price will take care of itself and suitors (welcome or not) will come calling. The big hammer on the minute-to-minute share price fluctuations and machinations is due to the market makers, traders and institutional holders as well as our new friends that will be coming on board.

Of course all of this is just IMO and the data is hopefully correct (please correct if wrong). And, please feel free to add information that adds to or possibly destroys the very good feeling I presently have. The landscape can change quickly. Always like to be up to date as much as possible.

Anyway, in closing, I'll ask - Did everyone enjoy yesterday/today's surprise? I know I did.

Regards,
WH

From Briefing at 10:22 this a.m.

Thermo Fisher: Goldman adds to Conviction Buy List; valuation discount is unwarranted (611.38 +3.15)
Analyst Matthew Sykes added, "We are adding Buy rated TMO to the Conviction List with a $690 price target representing 13% upside from current levels. We believe that TMO's 3-turn valuation discount to the sector is unwarranted for 3 main reasons: 1) we now have strong confidence the company can hit HSD growth, a material step up from their historical growth rate, a level we see as highly achievable and above sector peers, 2) TMO is experiencing multiple growth drivers across their end markets from robust funding in biopharma and academic/government, a cyclical rebound in industrial and continued pent up demand for their instrumentation, and 3) TMO is organically building a highly competitive bioprocessing business experiencing strong growth rates at highly accretive margins."

Businesses aren't really comparable due to scale, but positive note on bioprocessing should relate to CDMO too. About the time this note came out, CDMO started to leak higher.

Regards,
WH

peregr,

Have to love the analysts. Got the news from Breifing.com this morning around 7 a.m. cst about HGEN. Approximately 1 hr. later, the following note from the fearless Joe Pataginis appeared in Briefing.

Humanigen: Disappointing EUA Outcome But Lenzilumab Value Proposition Remains Intact; Target Reduced to $28 - H.C. Wainwright (15.11)
H.C. Wainwright's Joseph Pantginis states, "We reiterate our Buy rating though are reducing our price target to $28 from $36 based on the following factors: (1) adjustment to base year; (2) adjustement to fully diluted share count; and (3) pushing out our lenzilumab COVID-19 approval timelines in the U.S. and ex-U.S. to 2023 and 2024, respectively. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Our valuation is currently based on the two lead opportunities for lenzilumab: (1) COVID-19 (72% contribution); and (2) CAR-T therapy (28% contribution). Moving forward, we believe upside potential to our valuation exists based on: (1) attaining higher market penetration than currently projected; (2) adding additional indications to our valuation based on development stage and clinical data; and (3) augmenting projected chances of success based on clinical progress. Factors that could impede reaching our price target include failed or inconclusive clinical trials, the inability of the company to secure adequate funding to progress its drugs through the development pathway, the occurrence of dilutive capital raises, and lack of commercial success."

Regards,

WH

Amrsto1000,

"I'm buying the 23's, ..."

I'm with you. Hard to believe I just bought back the shares I sold yesterday at $28.22 at $23.24 - just a little over 24 hrs. later. Kind of wondering if that 60k+ gaggle of shares was sitting at $25 for the taking. 60k plus shares just purchased back at $23.25. Hmmm. Price/volume action.

Just FYI,

Was researching a new trade in BHVN. Went to the trusty International Business Daily stock checkup page. BHVN is in the Medical-Biomed/Biotech group. The group currently is rated fairly low at 134 out of 179 groups showing that they're not in high favor at the moment. But, these industry rankings move around quite a bit.

But, the long belated point that I'm trying to get to is that CDMO is currently rated #1 in this group! Never seen that before. REGN is number 2 and HALO is number 4 at present time. HGEN is currently number 282.

Just a few other tidbits from the category ratings that I always look at in my analyses:

Relative Strength Rating - 98% (that's excellent)
Accumulation/Distribution Rating - B+ (very good)
Up/Down Volume - 1.6 (again very good)
Qtrs of Increasing Fund Ownership - 4 (but we knew that)

Party on boys and girls.

Regards,
WH

Amrsto,

"Institutional Shares56,572,206 - 93.00% (ex 13D/G)"

You can't begin to understand how much this pleases me. Many, many, many moons ago, one of the investment sites listed the top five institutional holders and their holdings in TCLN. If I'd been an institution at that time, I would have slotted in at the 3rd spot. I knew I was taking a flyer and out on a limb with no wings at the time, but I still almost threw up.

Ah, the s-3 death spiral, the reverse splits, the discussions/arguments with Bymaster, Bonfiglio, King and Swartz, the re-brandings, etc., etc., etc. Any of you guys remember Legere. By my recollection, he saved the company so it could live another day after the s-3 debacle. Not sure if I should idolize or despise him since it's been quite the roller coaster ever since. Just kidding. Seemed like a good guy.

Bottom line, things have lined up nicely. Market pull, financial strength, operating expertise, legitimate CEO and management team, etc. But, that institutional ownership really paves the runway - gets my heart pumping. Biggest reason I'm still here boring you folks.

Good luck all,
WH

Bluerinse,

Thanks. I didn't even know they had a LinkedIn page. Weekly updates would be very nice indeed. Sometimes it's the easy stuff............

Regards,
WH

Nice breakout above 52 wk high. Now if we can get some solid end of day volume to add to the total, we can attract some more eyeballs. With the Institutional numbers now up, things seem to be clicking.

I often throw a few shares out/buy a few shares here and there to gauge interest. Offered a few about 15 minutes ago and felt like the market maker jumped through my computer to make me press the sell button. Interesting when you do a market sell and get a higher price than the last price showing on my TC-2000 graph.

Good luck all,

WH

Currently #4 on IBD's up gainers. They base it on volume increase.

Regards,
WH

21 minutes in and already at approximate daily average of last couple of months volume. Can we double daily volume in first hour? That'd catch some noticing eyes.

Regards,
WH

From Briefing.com today in case everyone missed it.

"CDMO Director bought 126,000 shares at $18.18 worth ~ $2.3 mln."

Don't know who.

Regards,
WH

I stand with stockaxe.

Regards,
WH

infofor2016,

"I'm good."

I'm with you. Biggest thing is CDMO has fundamentally changed from a strategy standpoint with St. Nick. Not content to slowly earn as you go to prosperity. The time is now in this space and CDMO just loaded up to become a player. I'm all for it. The opportunity is here. It's time to seize it.

I think it was stockaxe that mentioned this is just noise the last few days. I agree. Watched the minute price/vol bars on 3/4. CDMO went through resistance like a knife through butter on almost no volume. That doesn't happen. Yesterday's sell-off was interesting. Again, it's been explained, but just the big coupon purchasers getting their bennie. I hate it, but it's the way of the world and happens with every convertible issuance. CDMO is not unique.

Final thought. I saw someone mention an S-3 death spiral in biotechs the other day. Did the author of the post know that PPHM did and S-3 financing many moons ago? That CDMO is still around today is amazing.

Regards,
WH

Just fyi, I've been noticed by the mods that PLUG and FCEL aren't direct competitors and shouldn't be compared. However, on this board, I keep seeing how PLUG and solar are where things are at and FCEL is going to the dogs. So, I'll just put this out there.

From IBD today. The alt-energy group has dropped all the way down to 4th out of 197 industry categories after last weeks problems. Is 4th out of 197 pretty good?????? You tell me.

In the alt-energy category. FCEL is currently number 2 with it's accumulation/distribution rating dropping to A- and it's up/down volume coming in a 2. That says more of the big boys are buying rather than selling and the stock is under strong accumulation.

For comparison, PLUG has dropped to 17 in this category. Still excellent. They started the day with an accumulation/distribution rating of C, but by the end of the day it was up to B-. Their up/down volume comes in a 1.7. Certainly this performance is excellent. But.......... it's no FCEL.

BTW, for disclosure, I'm long both FCEL and PLUG.

Regards,
WH

So, many moons ago I attended a small re-cap conference with the featured speaker being Aubrey McClendon. Aubrey was originally an O&G landman, snarfing up oil leases undercover for the big boys. He then, with some partners decided to invest in their own leases and drill a few wells. Luck would have it that they hit pay dirt immediately and were off and running. But, it was a rocky road. So, his story was that they were up 1008% the first year and the toast of Wall Street. Year two was a bust and they were down 75% and almost bankrupt. Next year, up dramatically. Next year down. It was quite an interesting tale.

So, Aubrey finished up with a riddle and I'm making the numbers up somewhat. But, he asked, what do you have if you have something that's up 1008% the first year, down 75% the next year, up 300% the next year, down 50% the next year, etc., etc., etc. Everybody laughed and shook their heads, so Aubrey gave the answer. Well he said, "as a Chesapeake investor, if you'd survived the 5 heart attacks, you'd have been up a total of 750%!". His moral to the story. It'd been quite an up and down ride, but so far, lots of folks were happy.

I tell this story as I'm reminded that some posters showed up when FCEL was around $1.8 per share. Been crowing from the rooftops ever since that it's overvalued and headed down while claiming to be waiting to buy - ever since $1.80. But of course everyone knows that. So, let's see. FCEL in about a 6 month timeframe has moved from $1.80 (round numbers) up to almost $30. That's above a 1500% six month return. Annualize that if you want to. But of course, similar to Aubrey, FCEL today is merely at $18.69. What's that, a 900%+ number? Not too shabby. Of course, you investor/trader guys could just sit on the sidelines and listen to folks talk. Or.............

BTW, for some irony. FCEL today closed up $1.81. In a day it moved higher than the total price per share back when everyone here had a chance to purchase. Glad I haven't been sitting on the sidelines all this time.

Regards,
WH

Just fyi. PLUG announced earning pre-market today and "missed" by $1.00 which is the big headline. Details show that they had a huge expense due to retiring outstanding warrants that impacted the number greatly. Revenues were better than expected.

I mention this because FCEL has traded in the first few minutes in lockstep with PLUG. We'll see how it goes from here, but my opinion is that the PLUG news is good news for them since earnings going forward will be more transparent. I think that'll set in after the initial reaction, but we'll see. And, we'll see if FCEL divorces itself from PLUG.

Regards,
WH

That guy's an idiot. His "observations" on the oil industry aren't even correct. Everybody's an expert these days. Just ask your little friend.

Just fyi, this news is all over briefing.com. So we have that going for us.

Now the kicker. CDMO is currently the 2nd highest rated stock in the medical/biomed/biotech group in IBD's stock ranking. The med/biomed/biotech group is currently rated 55 out of the 197 groups IBD rates.

Might not mean much to other folks, but CDMO currently is carrying an A+ accumulation/distribution rating with an up/down volume of 2.4. To me, this is excellent and confirms what many of you have picked up on. It's hard to buy this stock at the current time.

Regards and happy news day.

WH

cabel,

Thanks for sharing the article. But, imho, this guy has strung together a bunch of stuff from wikipedia in an adhd sort of way. Outside of trying to hammer "hydrogen" stocks ..... maybe, he's all over the place.

I've seen the media politicizing the Texas energy outages in their usual soundbite way. For some data to make up your own mind, see the following:

https://www.zerohedge.com/markets/cascend-data-shows-wind-power-was-chief-culprit-texas-grid-collapse

Basically, the grid collapsing for whatever should be good for fuel cell companies, broadening their seat at the table. All imo.

Regards,
WH

Morning Campers! (Well, meant this to be pre-market but internet went down and I've been busy adjusting trades ever since.)

Anyway, thought some might be interested in the following data (which was gathered pre-open). Plenty of chart experts on here so won't go there. Everybody seems to like their version. You see what you want to see. So.......,

1. The alt-energy market is now the No. 1 rated industry out of the 197 sectors IBD rates. Not too shabby.

2. FCEL, as of this morning, had slid to the number 4 position in this group. For context, PLUG was rated 15, BE 18 and BLDP 21.

3. PLUG is currently carrying a composite rating of 92 and a relative strength rating of 99.

4. Most importantly, FCEL still maintains an A+ rating in the key accumulation/distribution arena. For reference, PLUG is A-, BE is C- and BLDP is B rated.

5. FCEL up/down volume is 1.8.

Enjoying my time much more since I took the "moron free" pledge. Also, I find inspiration in the following quote from Teddy Roosevelt.

"It is not the critic who counts; not the man who points out how the strong man stumbles, or where the doer of deeds could have done them better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood; who strives valiantly; who errs, who comes short again and again, because there is no effort without error and shortcoming; but who does actually strive to do the deeds; who knows great enthusiasms, the great devotions; who spends himself in a worthy cause; who at the best knows in the end the triumph of high achievement, and who at the worst, if he fails, at least fails while daring greatly, so that his place shall never be with those cold and timid souls who neither know victory nor defeat."

Just fyi, I'm long FCEL stock. I owned some 61 Puts in PLUG for a hedge that I exercised today and I picked up some July 16, 19 FCEL calls yesterday. Let's play ball!

Regards,
WH

Ho Hum,

Made a new resolution. Not going to address idiots anymore. Please help me as it won't be easy. So, if you see an idiot and me engaging them, please help me by calling me out. Certainly hope we never have to deal with such an animal on this site. But, you never know who might show up.

Just fyi. Don't know how things will close today. But, seeing that we opened the week on Monday at $24.12 and are now trading at $26.03 I'm feeling pretty good about life.

Regards and have a nice weekend,

WH

westjitter,

Just a couple of things. First from IBD.

1. CDMO is currently ranked 4th in the Medical, Biomed/Biotech space.
2. The Med, Biomed/Biotech space is rated 27th out of 197 industry groups.
3. CDMO's Composite Rating is 97 (Extremely high and hence the rating).
4. Relative Strength Rating is 92 - also excellent.
5. Key thing for me is that Accumulation/Distribution Rating is still A+
6. And, Up/Down Volume is 2.6

Items 5 and 6 speak to the accumulation that's going on.

Secondly, as back up. If you look at a colored daily candlestick chart with volume shown in bar chart form across the bottom, it's clear to see that green (up days) generally have very good volume and down days (red) are much weaker volume. Of course, a line graph of On Balance Volume (OBD) also shows this phenomena.

Big boys joining the party. Just mho.

Regards,
WH

Xena,

"So how come the AccDis line shows accumulation, not distribution?
"

Oh, oh, pick me, pick me. Can I play? The answer is: Because institutions are buying much higher volume than they are selling. Hence your readings, the A+ rating on IBD's proprietary acc/dis score, the 1.9 up/down volume score and a continuously rising OBV. Doesn't get much better than that.

Pretty obvious to me. I think I'd be pretty positive at this point even if I was Chicken Little.

Regards,
WH

BTW, pretty decent buying the last hour.